Cell Line Development Workflow

In order to generate high yields of recombinant protein products, cell lines such as CHO, Hybridoma or HEK 293 are typical platforms of choice. The process of developing stable cell lines starts with transfecting host cells (CHO or HEK 293) with recombinant plasmids or cell fusion for hybridomas. After transfection or cell fusion, large numbers of clones are screened and selected on the basis of expression of protein of interest (therapeutic biologics). Once candidate clones are identified, each “hit” is confirmed, validated, and characterized using DNA sequencing and a variety of downstream analytical assays. Upon completion, the lead clones are expanded and scaled up where bioprocesses occur.